3SOF

beaten stock.
couple of good news lately.
2.38 is not impossible near term.

Quote from: IdFix on December 20, 2006, 04:00:32 PM
Now...IMNR.OB has changed in IMRP.OB

As part of the reverse stock split, we also reduced our authorized number of common shares 100-fold, from 3.5 billion to 35 million.

reuters gives o/s 8.9M, so does co homepage:

CARLSBAD, CA – December 8, 2006 – The Immune Response Corporation (OTCBB: IMNR), an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases and HIV/AIDS, announced today that it will make a one-for-100 reverse stock split of its common stock. On a pre-split basis, Immune Response Corporation has approximately 900 million basic shares of common stock outstanding as of the end of trading on December 4, 2006. As a result of the reverse stock split, every 100 shares of common stock will be combined into one share of common stock and the total number of basic shares outstanding will be reduced to approximately 9 million. .....


well, latest SEC filing gives 35M s/o indeed.

Quote from: thai626 on December 21, 2006, 11:53:03 AM
Count me out!!  I didn't realize that the stock is so thinly traded.  Not worth my time yet.

volume 755k or about 5x average today. was quite a "feuerwerk" @2.92
somebody wanted desperately out and everything was swallowed instantly...

let's see what tomorrow will bring.

a bit more about MITI business.

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases.

Two product candidates are currently in clinical trials.

1.Adecatumumab (MT201) is a recombinant human monoclonal antibody which targets EpCAM expressing tumors with which Micromet has completed two phase 2 clinical trials, one in patients with breast cancer and the other in patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast cancer.

2.MT103 (MEDI-538), which is the first product candidate based on the novel a BiTE® product development platform, is being evaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkins lymphoma in conjunction with MedImmune. The BiTE® product development platform is based on a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful 'killer cells' of the human immune system.

in addition biopharmaceutical company is focusing on the development
of :

novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, is developing a monoclonal antibody inhibiting IL-2 signaling as potential novel immunosuppressant. Preclinical data on the compound, designated MT204 were  published online in the journal Molecular Immunology, october 2006

Potential use against Inflammatory Diseases, T Cell Leukemia and Transplant Rejection

MT110 (BiTE™), Solid Tumors, product candidate in Pre-clinical stage.

D93 (humanized antibody), Solid Tumors, product candidate in Pre-clinical stage.


Micromet has established collaborations with MedImmune and Serono.

got my attention some time ago with this news:

______________________________________________________________
Micromet Inc. traded 19 times more than usual, to about 1.6 million, after the drug developer said it extended a collaboration agreement on a new cancer drug with biotech Serono SA.

The drug, adecatumumab, is currently in trials for use in patients with metastatic breast cancer, and the extended agreement includes identifying the best dosing regime and exploration of additional uses for the drug. Under the deal, Serono will pay development costs.

Shares of Micromet rose almost 50 percent Monday after the Carlsbad, Calif.-based company said it received a $10 million milestone payment from Serono SA in connection to the drug development.
______________________________________________________________

O/S  31.4M
Float 19.5M

revenues jumpy as is graph.Price stabilized after peak.keeping on radar.
maybe one candidate for 3-4 fold gains next year.

gl

had a look on NYER 2-3 weeks ago.

stabile revenues for last 3 years, too low net income relative to rev., cash flow neg.
yes, you can gamble on either takeover with some premium or just wait for a 30% short price-peak.

too little fresh power for me in this stock.more like co-s with ability to surprise.

anyway, gl.

up 11% after news today with good vol.

6:05AM Kosan Biosciences announces license of motilin agonist program to Pfizer (KOSN) 4.88 : Co announces the establishment of a worldwide license agreement with Pfizer (PFE) for Kosan's motilin agonist program. The agreement includes Kosan's clinical candidate, KOS-2187 and related compounds. KOS-2187 has demonstrated improved gastric emptying in preclinical studies and may have therapeutic benefit in gastrointestinal diseases such as gastro- esophageal reflux disease, or diabetic gastroparesis.  Under the terms of the license agreement, the co and Pfizer will collaborate on filing of regulatory documents and initiation of a Phase 1 clinical trial of KOS-2187. Pfizer will be responsible for all development, regulatory and commercial activities related to the motilin agonist program. The co will receive an upfront payment of $12.5 mln and will be eligible to receive up to $250 mln for the successful development and commercialization of KOS-2187 for one indication, as well as royalties on worldwide sales. This total value of up to $250 mln includes development milestone payments of up to $72.5 mln. Should Pfizer elect to develop KOS-2187 for a second indication or to develop other the co compounds within the licensed rights, additional development and commercial milestones may be payable to the co as well as royalties on worldwide sales of any licensed Kosan product.

rayongthai is not a guru for investing in SIMC.i am talking about fundamentals as well.bet that here are lots of threads praising(hyping) , intentionally or not, stocks of co-s that do have remarkably worse fundamentals than our poor and crashed SIMC does. why not put a warning to all of those threads?

no need to mix spammers and companies!

penny stock section is almost 100% hype.
no use of pasting 3 times the same graph. this is spam.our eyes are ok.

i have spoken.gl.

i'd rather call it filling a gap of " crush day" , because of remarkably higher volume on gap up.... so definitly 75%buy here.....u could not convince me because of that 1( one ) day. no offence.gl

 melf:

your point of view here is as right and "proven in practice"  as is  the standpoint of rayongthai.....

do not take somebodys convinience in something so personally. maybe you got burned with low floaters. we all get burned sometimes.

if using various aliases is allowed here, so why your"warnings", i think users of 3st are sufficiently educated about pure hype. why don´t you trust your co-posters here?

there are facts in favour of buy recommendation for SIMC.
if you got nothing new to add to this thread, please cut this rosy noise of yours.

well, 2 words about why i have bought SIMC recently:

pro:

1.super low float - absolute as well as relative to all shares issued.
2.bullish price graph
3.RSI(37). historically if it stays hovering above 30, it never broke this but goes       UP. 
4.decent rev.growth YoY, profitable.
5.current market supports low floater/small cps rather than big cps.

contra:

1.don't like MACD
2.debt, think they're ready to raise some extra funding ( like CTTY did)

                                      * * *
volatility is not a problem for small speculator like me, hoping to catch 1-2 days'
price & vol. peak. 

using STOP and in only for short time.target 7.40.

gl everyone

that's over for this time.sold my only long position.

9mo  +103%

wanted to discuss some low floaters here, seems to be proper thread

markets are continuously on mood of taking low floaters up one by one.played some of them.
what are opinions about possible next rockets?

there are CTTY, SIMC, SPNS on my radar.

1. CTTY possibly acting like GOAM
2. SIMC flag forming + profitable
3.SPNS seems to be turnaround story after years of lagging.

buying time.oversold with light volume.picking up some for a start.

nice moves lately.also recommend to read about gift card business in Forbes' magazine.
this low floater can jump 10 fold.